COVID-19 reports:

Brief Dashboard

Development Status

The drugs and devices from our portfolio companies follow a clear development path from discovery to approval.

Current Therapeutics Development Status

Discovery
Pre-Ind
IND
Phase 1
Phase 2
Phase 3
Actuate 9-ING-41
Azitra ATR-12
Azitra ATR-04
Azitra ATR-02
Cognition Therapeutics CT-1812
Encore Vision EV-06
Immusoft MPSI
Immusoft MPSII
IN8bio ICY-100
IN8bio ICY-200
Lantern Pharma LP-300
Lantern Pharma LP-100
Lantern Pharma LP-184
Lung Therapeutics LTI-01
Lung Therapeutics LTI-03
Lung Therapeutics VAR-2355
ONL Therapeutics ONL1204
Opus Genetics OPGx-001
Opus Genetics OPGx-002
SIRPant SIRPant-M
Stream Therapeutics PDV
Trefoil Therapeutics TTHX1114
Taysha Gene Therapies TSHA-120
Taysha Gene Therapies TSHA-101
Taysha Gene Therapies TSHA-118

Current Devices Development Status

Development
FDA Approval
Commercial
Abilitech Abilitech Exo
410 Medical Lifeflow with fluids
410 Medical Lifeflow with blood
Top